Show simple item record

dc.contributor.authorStanhope, T. J.
dc.contributor.authorWhite, W. M.
dc.contributor.authorModer, K. G.
dc.contributor.authorSmyth, A.
dc.contributor.authorGarovic, V. D.
dc.date.accessioned2018-09-20T16:25:25Z
dc.date.available2018-09-20T16:25:25Z
dc.date.issued2012-08-09
dc.identifier.citationStanhope, T. J. White, W. M.; Moder, K. G.; Smyth, A.; Garovic, V. D. (2012). Obstetric nephrology: lupus and lupus nephritis in pregnancy. Clinical Journal of the American Society of Nephrology 7 (12), 2089-2099
dc.identifier.issn1555-9041,1555-905X
dc.identifier.urihttp://hdl.handle.net/10379/14001
dc.description.abstractSLE is a multi-organ autoimmune disease that affects women of childbearing age. Renal involvement in the form of either active lupus nephritis (IN) at the time of conception, or a IN new onset or flare during pregnancy increases the risks of preterm delivery, pre-eclampsia, maternal mortality, fetal/neonatal demise, and intrauterine growth restriction. Consequently, current recommendations advise that the affected woman achieve a stable remission of her renal disease for at least 6 months before conception. Hormonal and immune system changes in pregnancy may affect disease activity and progression, and published evidence suggests that there is an increased risk for a LN flare during pregnancy. The major goal of immunosuppressive therapy in pregnancy is control of disease activity with medications that are relatively safe for a growing fetus. Therefore, the use of mycophenolate mofetil, due to increasing evidence supporting its teratogenicity, is contraindicated during pregnancy. Worsening proteinuria, which commonly occurs in proteinuric renal diseases toward the end of pregnancy, should be differentiated from a IN flare and/or pre-eclampsia, a pregnancy-specific condition clinically characterized by hypertension and proteinuria. These considerations present challenges that underscore the importance of a multidisciplinary team approach when caring for these patients, including a nephrologist, rheumatologist, and obstetrician who have experience with these pregnancy-related complications. This review discusses the pathogenesis, maternal and fetal risks, and management pertinent to SLE patients with new onset or a history of LN predating pregnancy. Clin J Am Soc Nephrol 7: 2089-2099, 2012. doi: 10.2215/CJN.12441211
dc.publisherAmerican Society of Nephrology (ASN)
dc.relation.ispartofClinical Journal of the American Society of Nephrology
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/ie/
dc.subjectof-the-literature
dc.subjectrenal biopsy
dc.subjectfetal outcomes
dc.subjectantithrombotic therapy
dc.subjectmycophenolate-mofetil
dc.subjecterythematosus
dc.subjectdisease
dc.subjectsle
dc.subjecthydroxychloroquine
dc.subjectpreeclampsia
dc.titleObstetric nephrology: lupus and lupus nephritis in pregnancy
dc.typeArticle
dc.identifier.doi10.2215/cjn.12441211
dc.local.publishedsourcehttps://cjasn.asnjournals.org/content/7/12/2089.full.pdf
nui.item.downloads0


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland